+91 9891296838 / 9811747774
Dasatinib is used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who are positive for the Philadelphia chromosome.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of dasatinib Tablet brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the dasatinib Tablet medicine cost price in India.
The order for dasatinib Tablet will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Trade Name: Request you to fill the query form for more details.
Generic Name: dasatinib Tablet
Tablets: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.
60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand dasatinib Tablet on prescription and Import License in Patient's Name only.
For overseas patients, dasatinib Tablet can be made available in Send your enquiry to find dasatinib Tablet in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
Osimertinib Plus Dasatinib Appears Safe in Patients With EGFR-Positive NSCLC
Dasatinib Receives FDA Approval for Pediatric Ph+ ALL